MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Pfizer

Затворен

СекторЗдравеопазване

25.68 -2.21

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

25.63

Максимум

26.47

Ключови измерители

By Trading Economics

Приходи

-45M

2.9B

Продажби

938M

15B

P/E

Средно за сектора

13.984

37.257

EPS

0.78

Дивидентна доходност

6.21

Марж на печалбата

19.982

Служители

81,000

EBITDA

266M

5.3B

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+8.6% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

6.21%

2.94%

Следващи печалби

4.11.2025 г.

Следваща дата на дивидент

1.12.2025 г.

Следваща дата на екс-дивидент

7.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

16B

150B

Предишно отваряне

27.89

Предишно затваряне

25.68

Настроения в новините

By Acuity

36%

64%

150 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Pfizer Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.10.2025 г., 08:54 ч. UTC

Значими двигатели на пазара

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

30.09.2025 г., 15:07 ч. UTC

Значими двигатели на пазара

Pfizer Shares Rise After WSJ Reports Company Will Lower Drug Costs

22.09.2025 г., 14:54 ч. UTC

Придобивния, сливания и поглъщания

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- 2nd Update

22.09.2025 г., 11:51 ч. UTC

Придобивния, сливания и поглъщания

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

22.09.2025 г., 11:09 ч. UTC

Придобивния, сливания и поглъщания

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion

22.09.2025 г., 10:13 ч. UTC

Значими двигатели на пазара
Придобивния, сливания и поглъщания

Metsera Shares Leap Premarket on Report of Takeover by Pfizer

22.09.2025 г., 07:42 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Nears $7.3 Billion Metsera Deal, FT Says, Citing Sources

5.08.2025 г., 11:34 ч. UTC

Печалби

Pfizer Boosts 2025 Adjusted EPS Outlook Following 2Q Gains

22.09.2025 г., 15:17 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Jumps Back into the Weight-Loss Race With $4.9B Acquisition -- Barrons.com

22.09.2025 г., 13:43 ч. UTC

Придобивния, сливания и поглъщания

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

22.09.2025 г., 11:26 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Fox, Coinbase, Metsera, Pfizer, Kenvue, Anywhere Real Estate, Premier, and More -- Barrons.com

22.09.2025 г., 11:26 ч. UTC

Придобивния, сливания и поглъщания

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- WSJ

22.09.2025 г., 10:48 ч. UTC

Придобивния, сливания и поглъщания

Pfizer: Metsera Deal Adds Four Clinical-Stage Incretin, Amylin Programs to Pipeline >PFE MTSR

22.09.2025 г., 10:47 ч. UTC

Придобивния, сливания и поглъщания

Pfizer: Metsera Deal Includes Contingent Value Rights Worth Up to Additional $22.50/Share >PFE MTSR

22.09.2025 г., 10:46 ч. UTC

Придобивния, сливания и поглъщания

Pfizer: Metsera Deal Has Initial Enterprise Value of $4.9 Billion >PFE MTSR

22.09.2025 г., 10:45 ч. UTC

Придобивния, сливания и поглъщания

Pfizer to Pay Initial $47.50/Share for Metsera >PFE MTSR

22.09.2025 г., 10:45 ч. UTC

Придобивния, сливания и поглъщания

Pfizer to Acquire Metsera and Its Next-Generation Obesity Portfolio >PFE MTSR

22.09.2025 г., 09:12 ч. UTC

Горещи акции

Stocks to Watch Monday: Nippon Steel, Porsche, Infosys, Metsera -- WSJ

5.08.2025 г., 20:44 ч. UTC

Печалби

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5.08.2025 г., 18:20 ч. UTC

Печалби

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5.08.2025 г., 18:17 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5.08.2025 г., 16:04 ч. UTC

Пазарно говорене

Pfizer's New Tax Rate Helps Boost Adj EPS Outlook -- Market Talk

5.08.2025 г., 15:25 ч. UTC

Печалби

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5.08.2025 г., 13:56 ч. UTC

Печалби

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5.08.2025 г., 11:43 ч. UTC

Печалби

Pfizer Stock Pops as Earnings Smash Expectations. Guidance Hiked in Face of Tariffs. -- Barrons.com

5.08.2025 г., 11:27 ч. UTC

Печалби

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5.08.2025 г., 10:57 ч. UTC

Печалби

Pfizer Stock Pops as Earnings Smash Expectations. Why the Outlook Has Been Hiked. -- Barrons.com

5.08.2025 г., 10:55 ч. UTC

Печалби

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5.08.2025 г., 10:53 ч. UTC

Печалби

Pfizer Boosts 2025 Profit Estimate In A Sign Of 'Confidence' -- MarketWatch

5.08.2025 г., 10:51 ч. UTC

Печалби

Pfizer: On Track to Deliver About $7.2B Overall Cost Savings From Cost-Improvement Initiatives b/ End of 2027 >PFE

Сравнение с други в отрасъла

Ценова промяна

Pfizer Прогноза

Ценова цел

By TipRanks

8.6% нагоре

12-месечна прогноза

Среден 28.53 USD  8.6%

Висок 34 USD

Нисък 24 USD

Според 17 анализатори от Wall Street, предложили 12-месечна ценова цел за Pfizer през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

17 ratings

4

Купи

12

Задържане

1

Продай

Техническа оценка

By Trading Central

22.855 / 23.85Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

150 / 371 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat